Research shows that highly potent vaccine reduces the burden of herpes zoster and the incidence of postherpetic neuralgia in older adults.
Ciancio
Bruno C
BC
European Programme Intervention Epidemiology Training (EPIET), London, England. bruno.ciancio@hpa.org.uk
D017677:Age Distribution; D000368:Aged; D019433:Chickenpox Vaccine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006562:Herpes Zoster / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000453:epidemiology* / Q000517:prevention & control*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000627:therapeutic use
D019433:Chickenpox Vaccine; D014613:Vaccines, Attenuated